FDA Looks Into Possible Opioid, OTC Mix-Up at Novartis Plant

The FDA is looking into possible commingling of OTC drugs and prescription opioids at a Novartis Consumer Health plant as it works with the company to fix manufacturing problems there.
Drug Industry Daily